Pernix Therapeutics Holdings To Report Third Quarter 2011 Financial Results On November 15, 2011
Pernix Therapeutics Holdings, Inc. (NYSE Amex: PTX), a specialty
pharmaceutical company primarily focused on the pediatric market, today
announced that it will release its third quarter 2011 financial results
Pernix Therapeutics Holdings, Inc. (NYSE Amex: PTX), a specialty pharmaceutical company primarily focused on the pediatric market, today announced that it will release its third quarter 2011 financial results before the U.S. stock market opens on Tuesday, November 15, 2011 and has scheduled a conference call at 9:00 am EST that day to discuss the financial results. The conference call will feature remarks by Cooper Collins, Chief Executive Officer, and Tracy Clifford, Chief Financial Officer. To participate in the conference call, please dial (877) 604-9674 (domestic) or (719) 325-4916 (international). Participants can reference the passcode 2446267. Please dial in approximately 5 minutes prior to the call. The conference call will also be available via a live listen-only webcast and can be accessed through the Investor Relations section of the Company’s website, www.pernixtx.com. Please allow extra time prior to the call to visit the Company’s website and download any software that may be needed to listen to the webcast. A replay of the conference call will be available through November 22, 2011, at (888) 203-1112 (domestic) or (719) 457-0820 (international). The passcode for the replay is 2446267. An online archive of the webcast will be available on the Company's website for 30 days following the call. About Pernix Therapeutics Holdings, Inc. Pernix Therapeutics Holdings, Inc. is a specialty pharmaceutical company primarily focused on the sales, marketing, and development of branded and generic pharmaceutical products primarily for the pediatric market. The Company manages a portfolio of branded and generic products and Theobromine, a non-codeine, cough suppressant product candidate in development. The Company’s branded products include CEDAX®, an antibiotic for middle ear infections, Natroba™, a topical treatment for head lice marketed under an exclusive co-promotion agreement with ParaPRO, LLC and a family of prescription treatments for cough and cold (Brovex®, Aldex® and Pediatex®). The Company promotes its branded products through an established U.S. sales force. Pernix also markets generic products through its wholly-owned subsidiary, Macoven Pharmaceuticals. Founded in 1996, the Company is based in The Woodlands, TX.